Market News Archives

Gilead’s $7.8 Billion Bet on Arcellx: When CAR‑T Goes Prime Time for Multiple Myeloma -( $ACLX $GLD $XBI $IBB )

by John F. Heerdink, Jr. February 23, 2026 461Views 0Likes

Gilead Sciences (GLD) is paying up to $7.8 billion to acquire Arcellx (ACLX) , a longtime cell‑therapy partner, in a bid to turn a promising collaboration into a franchise‑defining pillar. Under the definitive agreement, Arcellx shareholders receive $115 per share in…

Google Buys Its Own Sunshine: Inside the $4.75 Billion Intersect Power Deal -( $GOOG $GOOGL )

by John F. Heerdink, Jr. February 23, 2026 435Views 0Likes

Alphabet’s decision to acquire Intersect Power for roughly $4.75 billion is less a vanity green purchase and more a hard‑nosed bet that the next edge in artificial intelligence will be measured in megawatts as much as in model parameters. In one stroke,…

Varda Space Aims to Turn Low Earth Orbit into Pharma’s New Production Line

by John F. Heerdink, Jr. February 23, 2026 439Views 0Likes

The new space economy is quietly adding an unexpected aisle to the drugstore: a “made‑in‑orbit” shelf where tomorrow’s pills may be grown, not in stainless-steel vats, but in microgravity factories looping Earth at Mach 25. Yes one day, your doctor’s prescription may…

Eupraxia’s Latest Raise: A Diffusphere-Fueled War Chest Aims at GI Disease -( $EPRX $IBB $XBI $SNY)

by John F. Heerdink, Jr. February 21, 2026 422Views 0Likes

In a market that has grown wary of “story stocks,” Eupraxia Pharmaceuticals (NASDAQ: EPRX) just delivered something refreshingly old-fashioned: a fully closed, upsized equity offering that actually funds a clinical plan rather than a marketing slogan. The clinical‑stage biotech, which trades on…

February 20, 2026- Tariffs, Tantrums, and a 1.1% Gain: Wall Street’s Surprisingly Chill Week -( $EPRX $NOK $NVDA $OPEN Rise!)

by John F. Heerdink, Jr. February 21, 2026 925Views 0Likes

US stocks finished the holiday‑shortened week ended Friday, February 20, 2026 higher, as a landmark Supreme Court decision scrapping President Trump’s emergency “Liberation Day” tariffs overshadowed softer growth data and firmer inflation readings.finance. Index performance S&P 500: up about 0.7% on Friday…

Earnings, Algorithms, PCE and Iran: What Could Possibly Go Wrong? -( $DIA $QQQ $SPY $VIX )

by John F. Heerdink, Jr. February 20, 2026 441Views 0Likes

Wall Street closed Thursday walking a now-familiar tightrope: cheering resilient earnings and AI-fueled innovation while eyeing rising US-Iran tensions and a looming inflation check that could jostle the Federal Reserve’s carefully choreographed exit from peak rates. Futures Lean Green As Geopolitics Heat…

February 19, 2026- Soft Landing, Hard Reality: What Today’s Sell‑Off Is Whispering to Patient Investors -( $DV $INTG $MODD $MTWO $NOK $OPEN $SER $VIX Rise!)

by John F. Heerdink, Jr. February 19, 2026 953Views 0Likes

U.S. stocks traded lower on Thursday, with major indexes pulling back after recent gains as investors digested Walmart earnings, a heavy data calendar, and still‑hawkish Fed signals. Indexes and macro The Dow Jones Industrial Average fell about 0.54% to roughly 49,395.16, while…

Carvana’s Earnings Hit a Speed Bump: Record Sales, Market Throws On the Parking Brake -( $CVNA $SPY )

by John F. Heerdink, Jr. February 19, 2026 439Views 0Likes

Carvana’s (CVNA) latest earnings report delivered record sales and solid profits, but Wall Street still sent the stock to the repair bay for a valuation realignment. Headline: Carvana’s Record Quarter Meets Wall Street’s Moodiness Carvana closed 2025 with a quarter that many…

February 18, 2026 – Stock Market Update: Tech Rebounds, AI Leaders and Small‑Cap Biotechs Move -( $DV $MCD $NOK $NVDA $OPEN $SER Rise!)

by John F. Heerdink, Jr. February 18, 2026 822Views 0Likes

U.S. stocks extended their rebound on Tuesday, February 18, 2026, with the major indexes logging another day of gains as investors grew more comfortable that AI‑related disruption fears and higher‑for‑longer interest rates are manageable for corporate earnings. Indexes and overall tone The…

GeoVax Expands Gedeptin Strategy: Riding Merck’s Keytruda Wave in a $200 Billion IO Market -( $GOVX $MRK $IBB $XBI )

by John F. Heerdink, Jr. February 18, 2026 597Views 0Likes

GeoVax’s (NASDAQ: GOVX) latest move to lock down combination rights for its Gedeptin cancer platform reads less like a routine licensing notice and more like an oncology strategy upgrade—complete with optionality, IP leverage, and a quietly ambitious grab for front-line real estate…

Market News

Your Guide To Staying Informed In The Markets